Key facts
- It has raised $8.4M; the latest was Accelerator/Incubator ($350K) in Sep 2025.
- Notable investors include Innovate UK, MedTech Innovator, Texas Medical Center, Matter (Consulting Services (B2B)), Future Planet Capital — 27 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 27 names
- ·Watchlist + deal alerts for 52North
- ·The full record, as it builds
Funding rounds
No funding rounds for 52North are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About 52North
Operator of a finger-prick blood test and digital platform designed to improve safety and quality of life for cancer patients at risk of sepsis. The company's device is portable, easy to use, and provides a measure of a patient's neutrophil count and C-Reactive Protein (CRP) Test at home, to identify the risk of neutropenic sepsis, the fatal side effect of chemotherapy, enabling patients to get access to a reliable, and cost-effective device which allows rapid management of the cancer condition.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2018
- Employees
- 25
- Website
- 52north.health/
- Ownership
- Privately Held (backing)
52North doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in 52North shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on 52North in its N-PORT filings yet. We sweep new filings monthly.